{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:22:41Z","timestamp":1781536961451,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study is to explore and analyze the FDA Adverse Event Reporting System (FAERS) database to identify drug adverse reaction signals associated with angioedema. The findings aim to provide valuable insights for clinical drug safety considerations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Open Vigil 2.1 data platform was utilized to collect adverse event reports related to angioedema from the first quarter of 2004 to the fourth quarter of 2023. The reporting odds ratio (ROR) and proportional reporting ratio (PRR) were employed as disproportionality measures to detect adverse reaction signals Sof drugs associated with angioedema.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 38,921 reports were retrieved, with the majority being reported by healthcare professionals. The analysis included predominantly adult patients (\u226518\u00a0years of age), with slightly higher representation of females compared to males. Among the top 30 drugs associated with the occurrence of angioedema, 24 drugs showed positive signals in the risk analysis. Based on the individual drug reporting odds ratio (95% confidence interval) as a measure of risk signal strength, the top five drugs are as follows: lisinopril [ROR (95% CI): 46.43 (42.59\u201350.62)], enalapril [ROR (95% CI): 43.51 (39.88\u201347.46)], perindopril [ROR (95% CI): 31.17 (27.5\u201335.32)], alteplase [ROR (95% CI): 29.3 (26.95\u201331.85)], ramipril [ROR (95% CI): 20.93 (19.66\u201322.28)]. After categorizing the drugs, the strongest positive signal was observed in the antithrombotic agents [ROR (95% CI): 22.53 (21.16\u201323.99)], following that, cardiovascular drugs [ROR (95% CI): 9.17 (8.87\u20139.48)], antibiotics [ROR (95% CI): 6.42 (5.91\u20136.96)], immunosuppressors [ROR (95% CI): 5.95 (5.55\u20136.39)], anti-inflammatory analgesics [ROR (95% CI): 4.65 (4.45\u20134.86)], antiallergic drugs [ROR (95% CI): 4.47 (3.99\u20135)], antiasthmatics [ROR (95% CI): 2.49 (2.14\u20132.89)], blood sugar control drugs [ROR (95% CI): 1.65 (1.38\u20131.97)], and digestive system drugs [ROR (95% CI): 1.59 (1.45\u20131.74)] exhibited progressively decreasing ROR values.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Many medications are associated with a high risk of angioedema. These medications play a crucial and potentially preventable role in controlling the occurrence of angioedema. It is essential to consider the risk level of drug-induced angioedema in clinical practice to optimize medication therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1417596","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T04:25:56Z","timestamp":1721103956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database"],"prefix":"10.3389","volume":"15","author":[{"given":"Maoxia","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaibin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"739044","DOI":"10.3389\/fcvm.2022.739044","article-title":"Anti-cancer drugs associated atrial fibrillation-an analysis of real-world pharmacovigilance data","volume":"9","author":"Ahmad","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e943407","DOI":"10.12659\/AJCR.943407","article-title":"A case of trauma-related angioedema of the airway in a patient on an angiotensin receptor blocker","volume":"25","author":"Allihien","year":"2024","journal-title":"Am. J. Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0132367","DOI":"10.1371\/journal.pone.0132367","article-title":"Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo","volume":"10","author":"Ashina","year":"2015","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1345\/aph.1P630","article-title":"The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"45","author":"Beavers","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J. Hypertens."},{"key":"B6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bjan.2019.01.005","article-title":"Postoperative angioedema induced by angiotensin-converting enzyme inhibitor: case report","volume":"69","author":"Bisinotto","year":"2019","journal-title":"Braz J. Anesthesiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaci.2014.04.016","article-title":"VE-cadherin, a potential marker for endothelial cell activation during hereditary angioedema attacks","volume":"134","author":"Bouillet","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.18176\/jiaci.0458","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema: from bed to bench","volume":"30","author":"Carucci","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.18176\/jiaci.0087","article-title":"Novelties in the diagnosis and treatment of angioedema","volume":"26","author":"Cicardi","year":"2016","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1001\/archinte.164.8.910","article-title":"Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment","volume":"164","author":"Cicardi","year":"2004","journal-title":"Arch. Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaip.2018.04.022","article-title":"Angioedema due to bradykinin dysregulation","volume":"6","author":"Cicardi","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/cvr\/cvq115","article-title":"Vascular permeability modulation at the cell, microvessel, or whole organ level: towards closing gaps in our knowledge","volume":"87","author":"Curry","year":"2010","journal-title":"Cardiovasc Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0230632","DOI":"10.1371\/journal.pone.0230632","article-title":"Angioedemas associated with renin-angiotensin system blocking drugs: comparative analysis of spontaneous adverse drug reaction reports","volume":"15","author":"Dubrall","year":"2020","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cvr\/cvq139","article-title":"The NO cascade, eNOS location, and microvascular permeability","volume":"87","author":"Dur\u00e1n","year":"2010","journal-title":"Cardiovasc Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s12024-018-0045-0","article-title":"Lethal manifestations of angioedema","volume":"15","author":"Gilbert","year":"2019","journal-title":"Forensic Sci. Med. Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3238\/arztebl.2017.0489","article-title":"Angioedema","volume":"114","author":"Hahn","year":"2017","journal-title":"Dtsch. Arztebl Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2332\/allergolint.12-RAI-0493","article-title":"Recent advances in drug-induced angioedema","volume":"61","author":"Inomata","year":"2012","journal-title":"Allergol. Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.clindermatol.2019.07.035","article-title":"Angioedema as a systemic disease","volume":"37","author":"Kazandjieva","year":"2019","journal-title":"Clin. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch. Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0018578718795271","article-title":"The newly available FAERS public dashboard: implications for health care professionals","volume":"54","author":"Kumar","year":"2019","journal-title":"Hosp. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000335621","article-title":"Drug-induced angioedema","volume":"97","author":"Lerch","year":"2012","journal-title":"Chem. Immunol. Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/joim.12304","article-title":"Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients","volume":"277","author":"Mansi","year":"2015","journal-title":"J. Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaci.2023.11.921","article-title":"Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus","volume":"153","author":"Mathey","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Jt. Bone Spine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.20452\/pamw.3273","article-title":"Bradykinin-mediated angioedema","volume":"126","author":"Obtu\u0142owicz","year":"2016","journal-title":"Pol. Arch. Med. Wewn."},{"key":"B26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1042\/cs0870567","article-title":"Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects","volume":"87","author":"Pellacani","year":"1994","journal-title":"Clin. Sci. (Lond)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/joim.12867","article-title":"Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study","volume":"285","author":"Rasmussen","year":"2019","journal-title":"J. Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00105-017-4119-9","article-title":"Drug-induced angioedema: focus on bradykinin","volume":"69","author":"Sachs","year":"2018","journal-title":"Hautarzt"},{"key":"B29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/00128071-200203090-00002","article-title":"NSAID-induced urticaria and angioedema: a reappraisal of its clinical management","volume":"3","author":"S\u00e1nchez-Borges","year":"2002","journal-title":"Am. J. Clin. Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"Stone","year":"2017","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"B32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pop.2022.11.003","article-title":"Urticaria and angioedema","volume":"50","author":"Szymanski","year":"2023","journal-title":"Prim. Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/HYPERTENSIONAHA.108.111393","article-title":"Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk","volume":"51","author":"Weber","year":"2008","journal-title":"Hypertension"},{"key":"B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/bmj.294.6564.91","article-title":"Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors","volume":"294","author":"Wood","year":"1987","journal-title":"Br. Med. J. Clin. Res. Ed."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1044744","DOI":"10.3389\/fphar.2022.1044744","article-title":"Drug-induced fall risk in older patients: a pharmacovigilance study of FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1417596\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T04:26:00Z","timestamp":1721103960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1417596\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":35,"alternative-id":["10.3389\/fphar.2024.1417596"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1417596","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"article-number":"1417596"}}